Taxotere is a chemotherapy drug used to treat malignant tumors. Its side effects include the development of osteonecrosis, which manifests as pain and swelling of bone tissue near the teeth. Osteonecrosis can lead to tooth loss from soft tissue surrounding the jaws being exposed because of lost bone around it.,
Long-term side effects of Taxotere and Cytoxan are cancer related. These drugs are used to treat breast, ovarian, lung, colon, rectal, or bladder cancer. The long-term side effects of these drugs can cause serious health problems including heart disease, stroke, blood clots, nerve damage and blindness.
Taxotere (docetaxel), a chemotherapy treatment, has been linked to irreversible hair loss, which an increasing number of women claim the maker, Sanofi, failed to tell them about.
Taxotere has been associated to irreversible hair loss, which many women claim the drug’s maker, Sanofi, failed to tell them about.
Hair loss (alopecia) is frequent during chemotherapy, although it nearly always comes back after the treatment is over. Cancer medications include a small risk of permanent hair loss, but it seems that the risk is larger with Taxotere than with other chemotherapy agents.
Sanofi has long advised physicians and patients in Canada and Europe about the potential of irreversible hair loss with Taxotere. In the United States, no such warning was issued until 2015.
Women are now launching Taxotere lawsuits, stating that the medicine caused them irreversible, disfiguring hair loss, that they were never told about this adverse effect, and that if they had known about the danger of permanent alopecia, they would have selected a different drug for treatment.
Hold Sanofi to account
Taxotere is a drug that is used to treat cancer.
Taxotere is a member of the taxanes family of cancer medicines. Taxane-based chemotherapy medications are one of the most potent families of chemotherapeutic treatments because they hinder cell development.
Taxotere, manufactured by Sanofi S.A., is remarkably similar to Taxol (paclitaxel), a taxane-based chemo medication manufactured by Bristol-Myers Squibb.
Taxotere was created to compete with Taxol. The key distinction between the two medications is that Taxotere was created as a taxane with a higher potency. Unfortunately, higher potency also equals more toxicity in this scenario.
Taxotere was first approved by the Food and Drug Administration (FDA) in 1994. The FDA turned down the request, citing the fact that Taxotere was more toxic than its competitor Taxol (which had already been approved by the FDA) and that more research into Taxotere’s side effects was required.
Long-term alopecia is a serious side effect of taxotere.
Taxotere was finally approved by the FDA in 1996. Taxotere was “recommended for the treatment of individuals with locally advanced or metastatic breast cancer following failure of previous chemotherapy,” according to the FDA.
Taxotere has been approved to treat a variety of malignancies after its first approval, including lung cancer, head and neck cancer, and prostate cancer.
Prescription material, on the other hand, still warns about poisonous fatalities and blood toxicity adverse effects. And, unlike Taxol, which has a modest chance of causing permanent hair loss, Taxotere has a high chance of causing long-term alopecia.
Taxotere and Alopecia Permanente
Hair loss is referred to as alopecia. It may affect the whole body, including the face, arms, legs, underarms, and pubic region, in addition to the head.
When the body incorrectly targets hair follicles, some individuals acquire alopecia as an autoimmune condition. Alopecia may also develop as a side effect of cancer treatment, when the cells that assist hair grow are damaged by chemotherapy and radiation.
Sanofi never willingly revealed the possibility of irreversible baldness with Taxotere.
Alopecia is not caused by all types of chemotherapy, and hair loss is typically temporary. Certain chemotherapy medicines are more likely to produce alopecia than others. Taxotere seems to have a higher risk of irreversible alopecia than other chemotherapy medications.
Permanent alopecia is a disfiguring disorder that affects women in especially. Women claim in lawsuits that Sanofi was aware of the danger of irreversible baldness from Taxotere but failed to adequately communicate this information to physicians and patients in the United States.
Sanofi asserts that just 3% of people who use the medication develop long-term baldness, however studies contradict this.
In 1998, Sanofi and Grupo Espaol de Investigacion en Cancer de Mama (GEICAM) started a long-term research named GEICAM 9805. According to research published in 2005, 9.2% of individuals who took Taxotere had hair loss that lasted up to ten years (and in some cases longer).
A study published in 2006 by a Colorado cancer specialist revealed that 6.3 percent of his Taxotere-treated patients had persistent hair loss years after stopping the medicine. “Why are you still suffering alopecia?” the same doctor remarked in an interview with A Head of Our Time, a nonprofit devoted to women coping with prolonged chemo-induced alopecia. It’s because you were on Taxotere.”
The findings of a questionnaire submitted to patients who took Taxotere and had persistent alopecia were presented at the 2014 National Cancer Research Institute (NCRI) Cancer Conference. 15.8% of respondents reported ongoing scalp hair loss, while others reported no regrowth of body hair in other areas.
Sanofi never willingly revealed the possibility of irreversible baldness with Taxotere. The FDA finally ordered a labeling revision in 2015 to reflect this danger, however it is not a black box warning (the FDA’s strictest warning kind).
Taxotere has been linked to irreversible hair loss, but no one knows why. According to one research, the medication causes toxic harm to hair cells or endocrine dysfunctions.
Hair regeneration treatments like minoxidil (Rogaine) may help, but they must be taken on a regular basis or any hair that comes back will fall out again. Another alternative is hair transplantation.
The FDA has issued a warning to a pharmaceutical company, and the company has been sued under the False Claims Act.
Following the FDA’s approval of Taxotere, Sanofi launched a marketing push to position the medicine as superior to other breast cancer drugs on the market.
Taxol is more successful than Taxotere, according to a 2008 research published in the New England Journal of Medicine.
Taxotere was touted as being better than Taxol, a medicine with a lesser potency (paclitaxel). The FDA rebuked Sanofi in a 2009 warning letter, claiming that promotional material issued by Sanofi was “false or misleading because it offers unsupported superiority claims and overstates the effectiveness of Taxotere,” according to the FDA.
Taxol is more successful than Taxotere for adjuvant therapy of breast cancer, according to a 2008 research published in the New England Journal of Medicine.
In 2015, a former employee filed a qui tam (False Claims Act) action against Sanofi, accusing the business of deceptively selling Taxotere and offering bribes and other incentives to doctors.
According to the employee, Aventis advertised Taxotere for off-label (unapproved) usage from 1996 to 2004.
According to the employee, the alleged scheme entailed instructing employees to misrepresent the drug’s safety and effectiveness for off-label uses (in order to expand the drug’s market) and paying healthcare providers kickbacks in the form of sham grants, speaking fees, and travel and entertainment to encourage them to prescribe Taxotere for off-label uses.
Taxotere income reportedly increased from $424 million in 2000 to $1.4 billion in 2004 as a result of the plan.
Suits Against Taxotere Are Being Filed
Did Sanofi conceal Taxotere’s irreversible hair loss dangers in order to boost revenues by fraudulently and illegally advertising the drug? In cases filed against the pharmaceutical industry, women say that this is the case.
The cases seek monetary damages for personal harm caused by Taxotere usage and inadequate Taxotere warnings. Psychological stress, medical expenditures, and lost wages are all examples of these injuries.
You may have a case if you or someone you know has lost their hair permanently after taking Taxotere. Contact us for a free case evaluation to see whether you are eligible for compensation.
“Taxotere and cytoxan side effects” is a long term side effect of Taxotere. It can cause serious problems like heart damage, blood clots, and kidney failure. Reference: taxotere and cytoxan side effects.
Frequently Asked Questions
What are the long-term effects of Taxotere?
A: The long-term effects of Taxotere are a decrease in white blood cells and platelets, which can cause anemia. Side effects may include nausea, vomiting, diarrhea, stomach pain/cramps, fever and chills.
How long does Taxotere side effects last?
A: It is unclear how long Taxotere side effects last because this medications length of use varies from one case to another. In general, it can take two or three months for the harmful side effects to fully disappear.
What are the cumulative side effects of Taxotere?
A: The cumulative side effects of Taxotere are the following. Side effects that last more than four weeks include neuropathy, bone marrow depression, and possible cancer. Side effects that happen within six months to a year may cause stroke or blood clots in veins or arteries.
- how long does docetaxel stay in your system
- worst days on taxotere
- how long do taxotere side effects last
- taxotere permanent hair loss percentage
- taxotere allergic reaction